Membrane fusion and drug delivery with carbon nanotube porins

Ho, Nga T.; Siggel, Marc; Camacho, Karen V.; Bhaskara, Ramachandra M; Hicks, Jacqueline M.; Yao, Yun‐Chiao; Zhang, Yuliang; Köfinger, Jürgen; Hummer, Gerhard; Noy, Aleksandr

doi:10.1073/pnas.2016974118

Cited by 30 publications

(26 citation statements)

References 45 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CNTPs could facilitate the fusion of lipid membranes, thus enhancing cellular uptake and the biocompatibility of CNTs [ 104 ]. Ho and co-workers demonstrated that liposomes studded with 0.8-nm-wide CNTPs were effective in delivering the drug to cancer cells and killing tumor cells (up to 90%) from fusion kinetics data and coarse-grained molecular dynamics ( Figure 6 E) [ 99 ].…”

Section: Drug Delivery In Vivomentioning

confidence: 99%

Precise Design Strategies of Nanotechnologies for Controlled Drug Delivery

Huang

2022

JFB

View full text Add to dashboard Cite

Rapid advances in nanotechnologies are driving the revolution in controlled drug delivery. However, heterogeneous barriers, such as blood circulation and cellular barriers, prevent the drug from reaching the cellular target in complex physiologic environments. In this review, we discuss the precise design of nanotechnologies to enhance the efficacy, quality, and durability of drug delivery. For drug delivery in vivo, drugs loaded in nanoplatforms target particular sites in a spatial- and temporal-dependent manner. Advances in stimuli-responsive nanoparticles and carbon-based drug delivery platforms are summarized. For transdermal drug delivery systems, specific strategies including microneedles and hydrogel lead to a sustained release efficacy. Moreover, we highlight the current limitations of clinical translation and an incentive for the future development of nanotechnology-based drug delivery.

show abstract

Section: Drug Delivery In Vivomentioning

confidence: 99%

Precise Design Strategies of Nanotechnologies for Controlled Drug Delivery

Huang

2022

JFB

View full text Add to dashboard Cite

show abstract

“…The problem of pulse or burst release of drugs is a major obstacle for drug delivery systems Materials 2022, 15, 4643 2 of 24 and drug-loaded implants [3]. To address this problem, many efforts have been made including surface engineering of implants by anodization [4], nanotube formation [5], coating strategies [6,7], micro-and nanoparticles [8,9], and polymerization [10].…”

Section: Introductionmentioning

confidence: 99%

UMAOH Calcium Phosphate Coatings Designed for Drug Delivery: Vancomycin, 5-Fluorouracil, Interferon α-2b Case

et al. 2022

View full text Add to dashboard Cite

Drug delivery systems based on calcium phosphate (CaP) coatings have been recently recognized as beneficial drug delivery systems in complex cases of bone diseases for admission of drugs in the localized area, simultaneously inducing osteoinduction because of the bioavailable Ca and P ions. However, micro-arc oxidation (MAO) deposition of CaP does not allow for the formation of a coating with sufficient interconnected porosity for drug delivery purposes. Here, we report on the method to deposit CaP-based coatings using a new hybrid ultrasound-assisted MAO (UMAOH) method for deposition of coatings for drug delivery that could carry various types of drugs, such as cytostatic, antibacterial, or immunomodulatory compositions. Application of UMAOH resulted in coatings with an Ra roughness equal to 3.5 µm, a thickness of 50–55 µm, and a combination of high values of internal and surface porosity, 39 and 28%, respectively. The coating is represented by the monetite phase that is distributed in the matrix of amorphous CaP. Optimal conditions of coating deposition have been determined and used for drug delivery by impregnation with Vancomycin, 5-Fluorouracil, and Interferon-α-2b. Cytotoxicity and antimicrobial activity of the manufactured drug-carrying coatings have been studied using the three different cell lines and methicillin-resistant S. aureus.

show abstract

“…However, the use of standard formulations of anticancer drugs does not always deliver the maximal concentration to the tumor [ 2 ], thus decreasing the probability of therapeutic efficacy and increasing the incidence of severe adverse effects [ 2 , 10 ]. Consequently, there is a need for anticancer drug formulations that can maximize the delivery of optimal concentrations of anticancer drugs to the tumors, while minimizing systemic adverse effects [ 9 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Lysinated Multiwalled Carbon Nanotubes with Carbohydrate Ligands as an Effective Nanocarrier for Targeted Doxorubicin Delivery to Breast Cancer Cells

et al. 2022

View full text Add to dashboard Cite

Multiwalled carbon nanotubes (MWCNTs) are elongated, hollow cylindrical nanotubes made of sp2 carbon. MWCNTs have attracted significant attention in the area of drug delivery due to their high drug-loading capacity and large surface area. Furthermore, they can be linked to bioactive ligands molecules via covalent and noncovalent bonds that allow for the targeted delivery of anticancer drugs such as doxorubicin. The majority of methodologies reported for the functionalization of MWCNTs for drug delivery are quite complex and use expensive linkers and ligands. In the present study, we report a simple, cost-effective approach for functionalizing MWCNTs with the carbohydrate ligands, galactose (GA), mannose (MA) and lactose (LA), using lysine as a linker. The doxorubicin (Dox)-loaded functionalized MWCNTs were characterized using FT-IR, NMR, Raman, XRD and FE-SEM. The drug–loaded MWCNTs were evaluated for drug loading, drug release and cell toxicity in vitro, in breast cancer cells. The results indicated that the carbohydrate-modified lysinated MWCNTs had greater Dox loading capacity, compared to carboxylated MWCNTs (COOHMWCNTs) and lysinated MWCNTs (LyMWCNTs). In vitro drug release experiments indicated that the carbohydrate functionalized LyMWCNTs had higher Dox release at pH 5.0, compared to the physiological pH of 7.4, over 120 h, indicating that they are suitable candidates for targeting the tumor microenvironment as a result of their sustained release profile of Dox. Doxorubicin-loaded galactosylated MWCNTs (Dox-GAMWCNTs) and doxorubicin loaded mannosylated MWCNTs (Dox-MAMWCNTs) had greater anticancer efficacy and cellular uptake, compared to doxorubicin–loaded lactosylated MWCNTs (Dox-LAMWCNTs) and pure Dox, in MDA-MB231 and MCF7 breast cancer cells. However, neither the ligand conjugated multiwall blank carbon nanotubes (GAMWCNTs, MAMWCNTs and LAMWCNTs) nor the lysinated multiwalled blank carbon nanotubes produced significant toxicity in the normal cells. Our results suggest that sugar-tethered multiwalled carbon nanotubes, especially the galactosylated (Dox-GAMWCNTs) and mannosylated (Dox-MAMWCNTs) formulations, may be used to improve the targeted delivery of anticancer drugs to breast cancer cells.

show abstract

Membrane fusion and drug delivery with carbon nanotube porins

Cited by 30 publications

References 45 publications

Precise Design Strategies of Nanotechnologies for Controlled Drug Delivery

Precise Design Strategies of Nanotechnologies for Controlled Drug Delivery

UMAOH Calcium Phosphate Coatings Designed for Drug Delivery: Vancomycin, 5-Fluorouracil, Interferon α-2b Case

Lysinated Multiwalled Carbon Nanotubes with Carbohydrate Ligands as an Effective Nanocarrier for Targeted Doxorubicin Delivery to Breast Cancer Cells

Contact Info

Product

Resources

About